Top Earnings & Economic Previews For The Day Ahead (ANF, A, NILE, CLWR, CMCSA, NVDA, PCG, DVN, DE, GG, WFR, NTAP, TEVA)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Abercrombie & Fitch Co. (NYSE: ANF) is expected to report $1.12 EPS on $1.33 billion in sales; shares are very close to 52-week lows and the downward channel in the chart continues.
Agilent Technologies, Inc. (NYSE: A) $0.69 EPS and $1.65 billion in sales. Interestingly enough, this one was one of the stocks outperforming Apple so far in 2012.
Blue Nile Inc. (NASDAQ: NILE) $0.42 EPS on $123.17 million.
Clearwire Corporation (NASDAQ: CLWR) -$0.35 EPS and $356.72 million in sales; we will be watching closely for any discussions about funding its business plan.
Comcast Corporation (NASDAQ: CMCSA) $0.41 EPS on $14.87 billion in sales; shares are very close to a 52-week high at $27.20 versus a high of $27.52.
NVIDIA Corporation (NASDAQ: NVDA) $0.19 EPS on $950.44 million in sales; expected 7% sales growth and a drop in earnings. The most recent Rambus pact details may become more clear as those patent agreements were not disclosed.
PG&E Corp. (NYSE: PCG) $0.85 EPS on $3.49 billion in sales. PG&E shares are off of highs more than other utilities in general and room for the 4.4% dividend to be discussed.
Devon Energy Corporation (NYSE: DVN) $1.48 EPS
Deere & Co. (NYSE: DE) $1.23 EPS on $6.49 billion in sales; watch currency discussions for guidance ahead.
Goldcorp Inc. (NYSE: GG) is one of the top gold companies with a $36.5 billion market value. Estimates are $0.60 EPS and $1.49 billion in revenue.
MEMC Electronic Materials Inc. (NYSE: WFR) is now down big again due to Energy Conversion Devices bankruptcy on fears that the solar sector is again going to crumble. This has moved from a value stock to a value trap now that it is expected to lose money. Estimates are -$0.06 EPS and $769.49 million in sales.
NetApp, Inc. (NASDAQ: NTAP) $0.58 EPS on $1.56 billion in sales; next quarter $0.63 EPS on $1.68 billion in sales; under $40 it is way under its 52-week high and now valued at only about 16.5-times fiscal April-2012 earnings estimates.
Teva Pharmaceutical Industries (NASDAQ: TEVA) is going to show whether or not generic ambitions can trump branded drugs. The turnaround in the share price has just not materialized. Estimates are $1.58 EPS and $5.63 billion in sales.
ECONOMIC DATA FOR WEDNESDAY:
- 8:30 AM EST Empire Manufacturing (Feb.)
- 9:15 AM EST January Industrial Production expected +0.6%
- 9:15 AM EST January Capacity Utilization expected 78.6%
- 10:00 AM EST NAHB optimism (Feb.)
- 10:00 Treasury’s Geithner testifies to House Ways & Means on 2013 budget
- 10:30 AM EST EIA Weekly Petroleum Inventory
- 2:00 PM EST FOMC Minutes
JON C. OGG
Contact [email protected] for any questions or corrections.